Drug Information

Drug General Information
Drug ID
D08KGY
Former ID
DNCL002724
Drug Name
PRX-302
Indication Prostate cancer [ICD9: 185; ICD10:C61] Phase 3 [524482]
Company
Sophiris
Target and Pathway
Target(s) Prostate specific antigen Target Info Modulator [531283]
KEGG Pathway Pathways in cancer
Prostate cancer
Pathway Interaction Database Coregulation of Androgen receptor activity
Regulation of Androgen receptor activity
FOXA1 transcription factor network
Reactome Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)
Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3
WikiPathways Prostate Cancer
Androgen receptor signaling pathway
References
Ref 524482ClinicalTrials.gov (NCT01966614) Randomized, Double-Blind, Vehicle-Controlled, Multicenter Safety and Efficacy Study of Intraprostatic PRX302 for LUTS BPH. U.S. National Institutes of Health.
Ref 531283Phase 1 and 2 studies demonstrate the safety and efficacy of intraprostatic injection of PRX302 for the targeted treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Eur Urol. 2011 May;59(5):747-54.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.